PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate

被引：0
|
作者：
Grocott, Rachel [1 ]
Metcalfe, Scott [2 ]
机构：
[1] PHARMAC, Wellington, New Zealand
[2] PHARMAC, Populat Med, Wellington, New Zealand
来源：
NEW ZEALAND MEDICAL JOURNAL | 2007年 / 120卷 / 1258期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：79 / 83
页数：5
相关论文
共 50 条
  • [41] Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses
    Kwok, Michelle Q. T.
    Kareem, Mistura A.
    Cash, Michael J.
    Lafferty, Fiona
    Tobin, Katy
    O'Mahony, James F.
    PHARMACOECONOMICS, 2020, 38 (08) : 809 - 818
  • [42] COST-EFFECTIVENESS AND COST-BENEFIT ANALYSES OF VACCINES
    WILLEMS, JS
    SANDERS, CR
    JOURNAL OF INFECTIOUS DISEASES, 1981, 144 (05): : 486 - 493
  • [43] Choosing a Time Horizon in Cost and Cost-effectiveness Analyses
    Basu, Anirban
    Maciejewski, Matthew L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (11): : 1096 - 1097
  • [44] Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis
    Mission, John F.
    Ohno, Mika S.
    Cheng, Yvonne W.
    Caughey, Aaron B.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (04)
  • [45] Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice
    Richardson, G
    Godfrey, L
    Gravelle, H
    Watt, I
    BRITISH JOURNAL OF GENERAL PRACTICE, 2004, 54 (507): : 765 - 771
  • [46] Cost-effectiveness of a potential future helicobacter pylori vaccine in the Netherlands; the impact of varying the discount rate for health
    Klok, R. M.
    de Vries, R.
    van der Zeijst, B.
    Postma, M. J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 726 - 726
  • [47] Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health
    de Vries, Robin
    Klok, Rogier M.
    Brouwers, Jacobus R. B. J.
    Postma, Maarten J.
    VACCINE, 2009, 27 (06) : 846 - 852
  • [48] The Wizards of Odds: Cost-Effectiveness, Barrett's Screening, and Surveillance Guidelines
    Perdue, David G.
    Murray, Joseph
    Wang, Kenneth K.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (10) : 865 - 867
  • [49] REVIEW OF ADMINISTRATION'S COST ASSUMPTION OF ROTAVIRUS AND PNEUMOCOCCAL VACCINES COST-EFFECTIVENESS ANALYSES
    De la Hoz-Restrepo, F.
    Castaneda-Orjuela, C. A.
    Alvis, N.
    Paternina, A.
    VALUE IN HEALTH, 2012, 15 (04) : A162 - A162
  • [50] EVALUATING THE COST-EFFECTIVENESS OF MULTICOMPONENT REHABILITATION GUIDELINES
    Mewes, J. C.
    Steuten, L. M. G.
    IJzerman, M. J.
    van Harten, W. H.
    VALUE IN HEALTH, 2013, 16 (03) : A30 - A30
12345